BONDUELLE Head office: "La Woestyne" - 59173 Renescure - FranceBonduelle a French S.C.A (Partnership limited by Shares) with a capital of 57 102 699,50 eurosRegistered under number: 447 250 044 (Dunkerque Commercial and Companies Register) 2024-2025 Annual results (July 1, 2024 - June 30, 2025) “Transform to win”: The Bonduelle Group achieves its first-year transformation plan objectives and initiates its recovery Message from Xavier Unkovic - Chief Executive Officer: For this 1st year of the “Transfor ...

Accessibility StatementSkip Navigation XI'AN, China, Sept. 9, 2025 /PRNewswire/ -- Bon Natural Life Limited (NASDAQ: BON) ("BON" or the "Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, today announced it has entered into a non-exclusive cooperation agreement with Beijing Huahai Keyuan Technology Co. Ltd. ("Huahai Keyuan") a prominent health products distributor in China. The term of the agreement is 24 months with a total contract value of US$18 mi ...

Core Points - Bon Natural Life Limited has received compliance notification from Nasdaq Stock Market LLC, confirming it has regained compliance with Listing Rule 5550(a)(2) [2][3] - The company will be subject to a one-year Discretionary Panel Monitor as part of the compliance process [2] - The matter regarding compliance is now officially closed as confirmed by Nasdaq [3] Company Overview - Bon Natural Life Limited is a Cayman Islands company that specializes in bio-ingredient solutions for the natural health and personal care industries [4]

Core Insights - The Bonduelle Group reported a slight decline in sales for FY 2024-2025, with total sales amounting to 2,203.8 million euros, reflecting a -0.8% change on a like-for-like basis and -0.9% on reported figures compared to FY 2023-2024 [3][22] - The company confirmed its objective of stable recurring operating income, supported by recovery in North American activities and strict cost control measures [5][18] Sales Performance - Sales for Quarter 4 of FY 2024-2025 showed a +0.2% increase on a like-for-like basis, while reported figures decreased by -0.2% [4] - The Europe Zone, accounting for 61.5% of business activity, experienced a decline of -3.9% on reported figures and -4.1% on a like-for-like basis [9] - The Non-Europe Zone, representing 38.5% of business activity, increased by +4.9% on a like-for-like basis and +4.4% on reported figures [12] Segment Analysis - Canned segment sales decreased by -4.4% to 1,070.5 million euros, while the frozen segment saw a -1.6% decline [7] - Fresh processed activities posted a +4.4% increase in sales, driven by strong performance in the prepared segment in France [11] Geographical Insights - North America returned to growth with +4.8% on a like-for-like basis, driven by the success of complete meal solutions [13] - The Eurasia region and Mercosur showed a +5.5% increase on a like-for-like basis, highlighting their role as growth drivers [14] Strategic Developments - The Bonduelle Group confirmed the sale of its packaged salad business in France, effective July 17, 2025, to the LSDH Group, which will continue using the Bonduelle brand under a licensing agreement [15][16] - The divested packaged salad business represented approximately 3.5% of the group's turnover, or 80 million euros for FY 2024-2025 [17]

Yongwei Hu, BON's CEO, stated, "Backed by the high druggability of our TCM-derived compound libraries and the efficiency of AI-powered screening technology, we are optimistic about Bon's potential to achieve meaningful breakthroughs in drug discovery. This initiative represents a strategic leap forward for our company and reinforces our long-term commitment to innovation in pharmaceutical research." XI'AN, China, July 30, 2025 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or "the Company"), ...

XI'AN, China, July 21, 2025 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural health and personal care industries, today announced it has entered into a non-exclusive sales distribution agreement with Beijing Huahai Keyuan Technology Co. Ltd. ("Huahai Keyuan"). The term of the agreement is 36 months with a total contract value of US$22 million. Pursuant to the agreement, Huahai Keyuan will sell and distribute ...

Core Viewpoint - The Bonduelle Group has confirmed the sale of its packaged salad business in France to the LSDH Group, effective July 17, 2025, as part of a strategic move to focus on fresh delicatessen markets amid declining salad consumption in France [2][3][4]. Group 1: Sale Details - The sale of the packaged salad business was initially announced on August 29, 2024, and became effective on July 17, 2025 [2][3]. - The divested business represented approximately 3.5% of Bonduelle's turnover, equating to €80 million for the 2024-2025 financial year [4]. Group 2: Strategic Focus - The Bonduelle Group aims to accelerate its activities in the fresh delicatessen market in France and Europe following the divestment [3][4]. - The LSDH Group will continue to use the Bonduelle brand for packaged salads in France through a licensing agreement [3][4]. Group 3: LSDH Group Overview - The LSDH Group is a family business with over 100 years of history, operating in six regions with ten production sites in France [8][9]. - The group employs 2,250 individuals and emphasizes social, societal, and environmental commitments in its operations [9].

Core Viewpoint - Bon Natural Life Limited has regained compliance with Nasdaq's continued listing requirements, allowing it to maintain its listing on the Nasdaq Capital Market [1][2]. Group 1: Compliance and Listing Status - On July 2, 2025, Bon Natural Life Limited received confirmation from the Nasdaq Hearings Panel that it has met the Minimum Bid Price Requirement under Nasdaq Listing Rule 5550(a)(2) [2]. - The Panel granted the Company's request to maintain its listing after Bon Natural Life Limited submitted a compliance plan on May 16, 2025, and presented its case during a hearing on June 5, 2025 [2]. - The Company will remain under a Discretionary Panel Monitor for one year, during which Nasdaq will oversee its ongoing compliance with all continued listing standards [3]. Group 2: Company Overview - Bon Natural Life Limited is a Cayman Islands company engaged in the natural, health, and personal care industries [4].

Group 1 - Bon Natural Life Limited (BON) has entered a non-exclusive sales distribution agreement with Beijing Huahai Keyuan Technology Co., Ltd. for a term of 24 months, with a total contract value of up to US$16 million [1] - The agreement allows Huahai Keyuan to market, sell, and distribute BON's natural prebiotic series products in the Chinese market [1] - BON's latest natural prebiotic product series features a "Prebiotic + Postbiotic" complex centered on super prebiotic stachyose, aimed at enhancing gut health by promoting beneficial probiotic populations [2][3] Group 2 - The partnership with Huahai Keyuan is expected to accelerate BON's entry into China's growing gut health market and unlock substantial growth opportunities for both companies [4] - Yongwei Hu, Chairman and CEO of BON, emphasized the strategic collaboration's potential to drive top-line growth and long-term shareholder value [4] - Huahai Keyuan is recognized for its strong market presence and expertise in introducing innovative health products to the Chinese market [4]

Core Insights - Bon Natural Life Limited has entered a non-exclusive sales distribution agreement with Tianjin Merrill-Youli Trading Co., Ltd. for a total contract value of up to US$18 million over 36 months [1] - The agreement focuses on marketing, selling, and distributing Bon's Ambroxide and related natural fragrance compounds in the Asia-Pacific region, primarily targeting the industrial fabric fragrance sector [1] Group 1: Product and Market Overview - Ambroxide is a synthetic molecule used in perfumery, known for its velvety, woody, and ambery scent, and serves as a cruelty-free alternative to natural ambergris [2] - The market for Ambroxide is expected to grow by over 25% each year for the next five years, with manufacturing scaling from thousands to tens of thousands of tons [2] Group 2: Strategic Partnership and Growth - The partnership with Merrill-Youli is expected to enhance Bon's market position in Ambroxide products and accelerate adoption in the Asia-Pacific fragrance markets [3] - Bon aims to leverage its advanced Ambroxide technology to boost sales growth and increase profitability in its fragrance chemicals business [3] Group 3: Innovation and Future Prospects - Bon has developed a biosynthetic alternative to Sclareol, a key natural ingredient for producing Ambroxide, with commercial launch expected soon [4] - The new production process is anticipated to scale rapidly and offer cost savings, enhancing overall efficiency and profitability [4] - This innovation is expected to strengthen Bon's competitive position and facilitate expansion into the larger textile fragrance market [5]